Detalhe da pesquisa
1.
A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis.
Ann Oncol
; 32(5): 652-660, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539944
2.
ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe.
Ann Oncol
; 28(11): 2633-2647, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28950323
3.
ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe.
Ann Oncol
; 27(8): 1423-43, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27457309
4.
Corrigendum to "ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe": Ann Oncol 2016; 27 (8): 1423-1443.
Ann Oncol
; 31(11): 1589, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32958358
5.
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
Ann Oncol
; 31(12): 1623-1649, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32979513
6.
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.
Br J Cancer
; 111(11): 2051-7, 2014 Nov 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-25268370
7.
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
Ann Oncol
; 24(9): 2278-84, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23704196
8.
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4).
Ann Oncol
; 29(8): 1634-1657, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30032243
9.
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
Ann Oncol
; 28(12): 3111, 2017 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28327998
10.
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
Ann Oncol
; 28(1): 16-33, 2017 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28177437
11.
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO).
Ann Oncol
; 25(9): 1673-1678, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24950979
12.
Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial.
Cancer Chemother Pharmacol
; 84(4): 839-847, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31428820
13.
XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.
BMC Cancer
; 8: 332, 2008 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-19014494
14.
Precision medicine in early breast cancer-beginning of a successful story?
ESMO Open
; 8(1): 100780, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36709708
15.
Hurdles and delays in access to anti-cancer drugs in Europe.
Ecancermedicalscience
; 8: 482, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25525460
16.
Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259].
Breast
; 32: 269-270, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28109648
17.
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).
Breast
; 31: 244-259, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27927580